New Findings from Affiliated Hospital of Southwest Medical University Describe Advances in Bone Research (Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases).
In: Health & Medicine Week, 2024-04-12, S. 3178-3178
serialPeriodical
Zugriff:
A recent report from the Affiliated Hospital of Southwest Medical University discusses new findings in bone research. The researchers developed a novel radiopharmaceutical called 177Lu-DOTA-IBA for the targeted diagnosis and treatment of bone metastases. The biodistribution and dosimetry of this radiopharmaceutical were evaluated using imaging and blood samples. The results showed that 177Lu-DOTA-IBA had fast uptake and high retention in bone lesions, with rapid clearance from the bloodstream. The absorbed doses in critical organs were within the safety limit, making 177Lu-DOTA-IBA a promising alternative for the targeted treatment of bone metastases. [Extracted from the article]
Copyright of Health & Medicine Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
New Findings from Affiliated Hospital of Southwest Medical University Describe Advances in Bone Research (Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases).
|
---|---|
Zeitschrift: | Health & Medicine Week, 2024-04-12, S. 3178-3178 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6459 (print) |
Sonstiges: |
|